I-Mab Highlights Promising Pharmacokinetics Findings for Uliledlimab
I-Mab recently presented pharmacokinetic and pharmacodynamic (PK/PD) modeling data from three Phase 1 studies, which emphasize important dosing information for upcoming clinical trials. The findings showed a notable correlation between the concentration of uliledlimab and the overall response rate (ORR) probability in patients with metastatic non-small cell lung cancer (mNSCLC). Additionally, the company is preparing to launch a randomized Phase 2 study that will combine uliledlimab with pembrolizumab and chemotherapy, expected to commence in the first half of 2025.
Insights from WCLC 2024
This presentation took place during the 2024 World Conference on Lung Cancer (WCLC 2024), organized by the International Association for the Study of Lung Disease, which brought together experts and innovators in lung cancer treatment. I-Mab, a global biotech company dedicated to advancing immunotherapy solutions, showcased its research on uliledlimab (TJ004309). This monoclonal antibody is designed to inhibit CD73, an enzyme that plays a crucial role in creating an immunosuppressive environment within tumors.
What is Uliledlimab?
Uliledlimab works by blocking CD73, aiming to restore the body's natural anti-tumor immunity. This mechanism is intended to enhance immunological responses and improve therapeutic outcomes. The data presented at the conference, derived from thorough PK/PD analyses across three Phase 1 studies, indicate that patients with treatment-naïve mNSCLC may particularly benefit from this innovative approach.
Key Study Findings
Dr. Phillip Dennis, Chief Medical Officer of I-Mab, highlighted the positive outcomes of their research. He stated, "The PK/PD analysis we presented reinforces our belief that uliledlimab is a potential best-in-class CD73 inhibitor. The encouraging exposure-response analysis demonstrates a promising relationship between uliledlimab levels and patient responses in NSCLC, alongside robust safety and target engagement findings."
Poster Overview and Statistical Highlights
The poster presented at the conference was titled: Integrated PK/PD Modeling for Uliledlimab, an Anti-CD73 Monoclonal Antibody, in Non-Small Cell Lung Cancer Patients (Poster #2979). The insights from the studies revealed several key points:
- About 95% of the modeled population reached the targeted therapeutic threshold with a 30 mg/kg dose of uliledlimab.
- Integrated analyses showed a significant positive correlation between uliledlimab's trough concentration and the likelihood of overall response in NSCLC cases.
- CD73 receptor occupancy exceeded 90% in peripheral B cells throughout the treatment period.
- The dosing regimen of 30 mg/kg followed by a boost on Cycle 1, Day 8 effectively maintained drug levels above the effective threshold of 80 µg/mL.
- The achievable trough concentration is associated with substantial clinical benefits, which may link to advantages in progression-free survival.
About I-Mab and Their Research Initiatives
I-Mab (NASDAQ: IMAB) is committed to innovating cancer treatments through advanced immunotherapy strategies. Based in Rockville, Maryland, the company focuses on harnessing scientific advancements to aid patients facing significant cancer challenges. With uliledlimab and other cutting-edge candidates in their pipeline, I-Mab is dedicated to enhancing cancer care continuously.
Frequently Asked Questions
What is uliledlimab designed to target?
Uliledlimab is specifically designed to target CD73, an enzyme that is essential for creating an immunosuppressive environment in tumors.
What were the major findings from the Phase 1 studies?
The studies revealed a positive correlation between uliledlimab concentrations and overall response rates in patients with metastatic non-small cell lung cancer.
When is the Phase 2 study of uliledlimab expected to begin?
The randomized Phase 2 study that combines uliledlimab with pembrolizumab and chemotherapy is anticipated to start in the first half of 2025.
How does uliledlimab work in treating cancer?
Uliledlimab inhibits CD73, which helps anti-tumor immunity to flourish, potentially reversing the immunosuppressive effects of adenosine in tumors.
What is I-Mab's goal in the oncology sector?
I-Mab aims to develop differentiated immunotherapy solutions to enhance outcomes for cancer patients worldwide, consistently pushing the boundaries of existing treatments.
